ARA-290 (Cibinetide) for Recovery
Investigational 11-amino-acid peptide derived from the helix-B region of erythropoietin that activates the innate repair receptor without stimulating red-blood-cell production; studied for small-fiber neuropathy.
Why ARA-290 (Cibinetide) for recovery?
According to PubMed, a randomized double-blind pilot in 22 sarcoidosis patients with small-fiber neuropathy found IV ARA-290 (2 mg, three times weekly for 4 weeks) significantly improved neuropathy symptom scores versus placebo with no safety concerns (Heij L et al., Mol Med 2012). A 2014 review of two Phase 2 trials reported consistent symptom improvement plus increased corneal nerve fibers without stimulating erythropoiesis (van Velzen M et al., Expert Opin Investig Drugs 2014). It is investigational and not approved.
Recovery context: Accelerating soft-tissue, tendon, gut, and post-training repair. ARA-290 (Cibinetide) fits this goal because its category (Recovery) and benefit profile align with the underlying mechanism.
Benefits relevant to recovery
- Activates the innate repair receptor to promote tissue protection and healing
- Increased corneal nerve fiber measures (a marker of small-nerve regeneration) without raising hematocrit
Reference dosing by bodyweight
Anchored to the most-cited research dose (2000 mcg @ 75 kg). Reference only.
| Bodyweight band | Reference dose range |
|---|---|
| <60 kg / <132 lb | 1247–1687 mcg |
| 60–75 kg / 132–165 lb | 1530–2070 mcg |
| 75–90 kg / 165–198 lb | 1870–2530 mcg |
| 90–105 kg / 198–231 lb | 2210–2990 mcg |
| >105 kg / >231 lb | 2550–3450 mcg |
Side effects to weigh against recovery benefit
- Generally well tolerated in trials
- Injection-site reactions
- Long-term safety not established
Also researched for
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.